<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><description>世事洞明皆学问，人情练达即文章</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 24 Mar 2021 09:56:53 +0800</pubDate><image><url>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</url><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>10分钟恢复血糖水平！FDA批准速效低血糖症新药</title><link>https://mp.weixin.qq.com/s/wxBTMZREEmI4ie1jG_UeiQ</link><description></description><content:encoded><![CDATA[10分钟恢复血糖水平！FDA批准速效低血糖症新药]]></content:encoded><pubDate>Wed, 24 Mar 2021 07:36:24 +0800</pubDate></item><item><title>康宁杰瑞公布2020年全年财务业绩及公司进展</title><link>https://mp.weixin.qq.com/s/-oIkn7jt3mpjTjnwKXTw-w</link><description></description><content:encoded><![CDATA[康宁杰瑞公布2020年全年财务业绩及公司进展]]></content:encoded><pubDate>Wed, 24 Mar 2021 07:36:24 +0800</pubDate></item><item><title>腾盛博药完成1.55亿美元C轮融资</title><link>https://mp.weixin.qq.com/s/ssCb5ofMGd_2ueS1WvfKdQ</link><description></description><content:encoded><![CDATA[腾盛博药完成1.55亿美元C轮融资]]></content:encoded><pubDate>Wed, 24 Mar 2021 07:36:24 +0800</pubDate></item><item><title>百奥泰再冲港股IPO</title><link>https://mp.weixin.qq.com/s/BIy7luByaolb1gitRR13Og</link><description></description><content:encoded><![CDATA[百奥泰再冲港股IPO]]></content:encoded><pubDate>Wed, 24 Mar 2021 07:36:24 +0800</pubDate></item><item><title>曙方医药与左手医生达成战略合作，共建罕见病全程智慧管理平台</title><link>https://mp.weixin.qq.com/s/gab-hYyJkZooJlRfaXRSag</link><description></description><content:encoded><![CDATA[曙方医药与左手医生达成战略合作，共建罕见病全程智慧管理平台]]></content:encoded><pubDate>Wed, 24 Mar 2021 07:36:24 +0800</pubDate></item><item><title>启德医药ADC酶催化偶联技术浅析</title><link>https://mp.weixin.qq.com/s/doPjSXQ4XWhd895hxpBFTw</link><description></description><content:encoded><![CDATA[启德医药ADC酶催化偶联技术浅析]]></content:encoded><pubDate>Tue, 23 Mar 2021 07:34:39 +0800</pubDate></item><item><title>专访 | 北京大学第三医院魏蕊：GCGR抗体促进β细胞再生，治愈1型糖尿病新希望</title><link>https://mp.weixin.qq.com/s/XHTaaYgEYgvpc5wW6jyzDg</link><description></description><content:encoded><![CDATA[专访 | 北京大学第三医院魏蕊：GCGR抗体促进β细胞再生，治愈1型糖尿病新希望]]></content:encoded><pubDate>Tue, 23 Mar 2021 07:34:39 +0800</pubDate></item><item><title>IL-17单抗专利布局</title><link>https://mp.weixin.qq.com/s/MvG57_ls5N2mY2Ag8T9PSg</link><description></description><content:encoded><![CDATA[IL-17单抗专利布局]]></content:encoded><pubDate>Mon, 22 Mar 2021 07:35:38 +0800</pubDate></item><item><title>关注！BioChina中国生物医药创新高峰论坛</title><link>https://mp.weixin.qq.com/s/Sj-ix84cHru-VABPTzWCBg</link><description></description><content:encoded><![CDATA[关注！BioChina中国生物医药创新高峰论坛]]></content:encoded><pubDate>Mon, 22 Mar 2021 07:35:38 +0800</pubDate></item><item><title>生物分析专栏 | 治疗性蛋白药物免疫原性分析</title><link>https://mp.weixin.qq.com/s/7BBF7WZToeOQ3YrVcPB6bA</link><description></description><content:encoded><![CDATA[生物分析专栏 | 治疗性蛋白药物免疫原性分析]]></content:encoded><pubDate>Sun, 21 Mar 2021 08:34:27 +0800</pubDate></item><item><title>招聘 | 选择魔方，选择成长</title><link>https://mp.weixin.qq.com/s/SpLFIPlKRuEVJCYVNUEdQw</link><description></description><content:encoded><![CDATA[招聘 | 选择魔方，选择成长]]></content:encoded><pubDate>Sun, 21 Mar 2021 08:34:27 +0800</pubDate></item><item><title>CDMO整合加速</title><link>https://mp.weixin.qq.com/s/ZGEF_k8LnWfGp6nq0cS2hA</link><description></description><content:encoded><![CDATA[CDMO整合加速]]></content:encoded><pubDate>Sat, 20 Mar 2021 08:46:56 +0800</pubDate></item><item><title>【聚焦PROTAC】118个在研热门靶点</title><link>https://mp.weixin.qq.com/s/IvdkR-VOir31YJ7D0EQv9g</link><description></description><content:encoded><![CDATA[【聚焦PROTAC】118个在研热门靶点]]></content:encoded><pubDate>Sat, 20 Mar 2021 08:46:56 +0800</pubDate></item><item><title>再鼎医药「瑞派替尼片」即将获批上市</title><link>https://mp.weixin.qq.com/s/wftqv-ks5QZcAUu6kR8-6A</link><description></description><content:encoded><![CDATA[再鼎医药「瑞派替尼片」即将获批上市]]></content:encoded><pubDate>Sat, 20 Mar 2021 08:46:56 +0800</pubDate></item><item><title>靶向c-Met：特泊替尼 vs 卡马替尼 vs 赛沃替尼</title><link>https://mp.weixin.qq.com/s/QT-kHFF8hQ9rh5Q82qBJPQ</link><description></description><content:encoded><![CDATA[靶向c-Met：特泊替尼 vs 卡马替尼 vs 赛沃替尼]]></content:encoded><pubDate>Fri, 19 Mar 2021 08:00:33 +0800</pubDate></item><item><title>Science子刊：关键靶点Prosaposin浮出水面，动脉粥样硬化或迎来RNAi疗法！</title><link>https://mp.weixin.qq.com/s/sMvAA5c3C-VPjAYAOMg09Q</link><description></description><content:encoded><![CDATA[Science子刊：关键靶点Prosaposin浮出水面，动脉粥样硬化或迎来RNAi疗法！]]></content:encoded><pubDate>Fri, 19 Mar 2021 08:00:33 +0800</pubDate></item><item><title>远大医药2020年业绩：净利润增长56%，科技创新布局厚积薄发</title><link>https://mp.weixin.qq.com/s/d26eXVyG10mDcuMib0MjEA</link><description></description><content:encoded><![CDATA[远大医药2020年业绩：净利润增长56%，科技创新布局厚积薄发]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>Tecentriq vs Keytruda：三阴乳腺癌竞争白热化，一图尽览核心临床布局</title><link>https://mp.weixin.qq.com/s/VRCgsHxhp0ZN695HE5IhlA</link><description></description><content:encoded><![CDATA[Tecentriq vs Keytruda：三阴乳腺癌竞争白热化，一图尽览核心临床布局]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>PD-1抗体“新搭档”：融合IL-21，抗肿瘤疗效大大提升 | Nature子刊</title><link>https://mp.weixin.qq.com/s/TLUS4hQyF-K7Hk8sSHChLQ</link><description></description><content:encoded><![CDATA[PD-1抗体“新搭档”：融合IL-21，抗肿瘤疗效大大提升 | Nature子刊]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>保诺—桑迪亚搭建PROTAC研发平台，助力“不可成药性”为“高成药性”</title><link>https://mp.weixin.qq.com/s/1pY5a5JB3OqLlT5avF4p4Q</link><description></description><content:encoded><![CDATA[保诺—桑迪亚搭建PROTAC研发平台，助力“不可成药性”为“高成药性”]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item></channel></rss>